A Phase 1/2 Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma and Leiomyosarcoma.
Michael J WagnerYuzheng ZhangLee D CranmerElizabeth Trice LoggersR Graeme BlackSabrina McDonnellShannon MaxwellRylee JohnsonRoxanne MoorePedro Hermida de ViveirosLauri AicherKimberly S SmytheQianchuan HeRobin L JonesSeth M PollackPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Although the trial did not meet the primary objective response rate endpoint, PFS compared favorably with prior studies of trabectedin warranting further investigation.